← Pulse/Companies

Ollin Biosciences on Pulse

Biotech

The full thread of our Ollin Biosciences coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Jun 25, 2026
Since

Coverage Timeline

newest first
  1. FUNDINGOllin Biosciences Raises $330M Series B to Advance Its Therapeutics Pipeline→
  2. FUNDINGOllin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies→

All Coverage

FUNDING$330M

Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics Pipeline

Ollin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.

Jun 26, 2026
FUNDING$330M

Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies

Ollin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.

Jun 25, 2026